Next 10 |
2024-05-31 15:00:19 ET More on the markets Bitcoin's Fading Action Is A Huge Warning For Stock Market Liquidity S&P 500: It Is All About Liquidity SPY: Time To Be Contrarian And Underweight Hedge funds back at record exposure to Magnificent 7 S&am...
2024-05-29 11:00:21 ET Yasmeen Rahimi from Piper Sandler issued a price target of $336.00 for MDGL on 2024-05-29 09:13:00. The adjusted price target was set to $336.00. At the time of the announcement, MDGL was trading at $221.755. The overall price target consensus is a...
CONSHOHOCKEN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced ten data presentations at the upcoming European Association for the Study...
2024-05-28 17:45:19 ET Summary Today, we take a more in-depth look at Altimmune, Inc., a biotechnology company focused on developing therapies for obesity and liver disease. The company's key asset is pemvidutide, a GLP-1 agonist that has shown some potentially promising results i...
2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...
2024-05-21 09:45:00 ET Madrigal Pharmaceuticals ' (NASDAQ: MDGL) shares are down by 27% over the past year, while the S&P 500 is up by 26%. However, this poor performance hardly reflects the progress the biotech has made. Madrigal recently earned regulatory approval for Rezd...
2024-05-16 08:21:28 ET Paulson & Co., the hedge fund founded by John Paulson, increased its stakes in NovaGold ( NG ) to 27.24M from 23.54M shares, International Tower Hill Mines ( THM ) to 64.2M from 61.93M shares and Madrigal Pharmaceuticals (NASDAQ:MDGL) during Q1, accordin...
2024-05-07 11:56:08 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Madrigal Pharmaceuticals (NASDAQ: MDGL ) just reported results for the first quarter of 2024. Madrigal Pharmaceuticals reported earnings per share of -$7.38. This was belo...
2024-05-07 11:24:02 ET Madrigal Pharmaceuticals (MDGL) Q1 2024 Results Conference Call May 07, 2024 8:00 AM ET Company Participants Tina Ventura - Chief IRO Bill Sibold - CEO Mardi Dier - CFO Conference Call Participants Yasmeen Rahimi - Piper Sandler...
2024-05-07 10:44:37 ET More on Madrigal Pharmaceuticals Madrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Label Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage Madrigal: Accelerated Rezdiffra Approval Puts It In The NAS...
News, Short Squeeze, Breakout and More Instantly...
Madrigal Pharmaceuticals Inc. Company Name:
MDGL Stock Symbol:
NASDAQ Market:
Madrigal Pharmaceuticals Inc. Website:
2024-05-29 11:00:21 ET Yasmeen Rahimi from Piper Sandler issued a price target of $336.00 for MDGL on 2024-05-29 09:13:00. The adjusted price target was set to $336.00. At the time of the announcement, MDGL was trading at $221.755. The overall price target consensus is a...
CONSHOHOCKEN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced ten data presentations at the upcoming European Association for the Study...
2024-05-21 09:45:00 ET Madrigal Pharmaceuticals ' (NASDAQ: MDGL) shares are down by 27% over the past year, while the S&P 500 is up by 26%. However, this poor performance hardly reflects the progress the biotech has made. Madrigal recently earned regulatory approval for Rezd...